Interventional trials in ENR-RND – Ataxia and HSP DiseaseTreatmentCenterContactKey information Friedreich AtaxiaVatiquinoneParis Brain Institute - Pitié Sapetriere University Hospital Paris France*protected email*" style="color: #009900;">Contact SCA3TrehaloseHospital Clinic Barcelona Spain*protected email*">ContactPatient recruitment temporarily halted Hereditary Spastic ParaplegiaUniversity Hospital Innsbruck Austria*protected email*">Contactnot yet registered SCA1 and SCA3Antisense oligonucleotide, intrathecally injected; phase1/2ARadboud university medical center Nijmegen Netherlands*protected email*">ContactRecruitment of Dutch patients only Friedreich AtaxiaOmaveloxolonFondazione IRCCS Istituto Neurologico Carlo Besta Milan Italy Friedreich AtaxiaPhase 3Bambino Gesù — Children's Hospital Rome Italy Friedreich AtaxiaVatiquinoneBambino Gesù — Research Hospital Rome Italy*protected email*">Rene Gallegos - Associate Director Clinical Operations MOVE-FA*protected email*">Briana Johnson - Manager Clinical Operations PTC743-003e FRDAN/ATUH Dublin Ireland*protected email*">Contact SCA and CANVASrTMSUniversity Hospital Bonn Germany*protected email*">Contact MSAi.v. TAK-341DZNE Bonn Germany*protected email*" style="color: #007acc;">Contact SCA1, SCA3, HuntingtonASODZNE Bonn Germany*protected email*">Contact SCA3Intrathecal ASODZNE Bonn Germany*protected email*">Contacttrial stopped Friedreich AtaxiaOmaveloxolonCenter for rare movement disorders Innsbruck Austria*protected email*">Contact